Sign In
Buy TSHA
$5.86
-0.0150 (-0.255%)
At Close: Jul 31, 2026
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
11:05am, Tuesday, 06'th May 2025
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 02'nd May 2025
DALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-ba
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 04'th Apr 2025
DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
02:25pm, Monday, 31'st Mar 2025
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 07'th Mar 2025
DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus (A
Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript
02:54pm, Wednesday, 26'th Feb 2025
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Hayleigh Collins - Director & Head of Investor Relations Sean Nolan - Chie
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates
10:15am, Wednesday, 26'th Feb 2025
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.35 per share a year ago.
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
08:00am, Wednesday, 26'th Feb 2025
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
08:00am, Wednesday, 19'th Feb 2025
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 07'th Feb 2025
DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b
Taysha Gene Therapies Is Showing Promise For Rett Syndrome
07:53pm, Monday, 27'th Jan 2025
Taysha Gene Therapies' TSHA-102 tackles Rett syndrome's root cause with its miniMECP2 transgene and scAAV delivery. So far, this is TSHA's main value driver, and it appears safe and effective in both
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 03'rd Jan 2025
DALLAS, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 06'th Dec 2024
DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b
U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Thursday.
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript
10:48pm, Wednesday, 13'th Nov 2024
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director and Head, Investor Relations Sean Nolan - Chie
